Jim Simons Iterum Therapeutics PLC Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.19 - $0.36 $40,888 - $77,472	215,200 Added 199.07%	323,300 $65,000
Q1 2022 May 13, 2022	SELL	$0.31 - $0.45 $5,921 - $8,595	-19,100 Reduced 15.02%	108,100 $38,000
Q4 2021 Feb 11, 2022	SELL	$0.39 - $0.74 $201,773 - $382,851	-517,367 Reduced 80.27%	127,200 $50,000
Q3 2021 Nov 12, 2021	SELL	$0.54 - $2.29 $1.43 Million - $6.06 Million	-2,644,733 Reduced 80.4%	644,567 $360,000
Q2 2021 Aug 13, 2021	BUY	$0.97 - $2.39 $3.19 Million - $7.86 Million	3,289,300 New	3,289,300 $7.6 Million
Q1 2021 May 13, 2021	SELL	$0.97 - $2.73 $710,913 - $2 Million	-732,900 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$0.46 - $1.2 $337,134 - $879,480	732,900 New	732,900 $725,000

145

Ticker ITRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,233,400
Market Cap $23M
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.